XML 36 R26.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following potentially dilutive securities have been excluded from the computations of weighted average shares of Common Stock outstanding as of March 31, 2025 and 2024, respectively, as they would be anti-dilutive:

 

   2025   2024 
   As of March 31, 
   2025   2024 
Shares underlying options outstanding   304,125    618,847 
Shares underlying warrants outstanding   12,873,602    8,838,717 
Shares underlying unvested restricted stock   430,474    297,862 
Anti-dilutive securities   13,608,201    9,755,426 
SCHEDULE OF REVENUE RECOGNITION

 

   2025   2024 
   For the Three Months Ended
March 31,		 
   2025   2024 
Patient service fees1  $1,570,382   $2,149,049 
Histology service fees   263,754    237,972 
Medical director fees   16,588    16,058 
Department of Defense observational studies   —    2,885 
Other revenues   2,873    427 
Total net revenue  $1,853,597   $2,406,391 

 

 

  1 Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $169,000 and $45,000 for the three months ended March 31, 2025 and 2024, respectively.
SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE

Property and equipment are carried at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the asset. Amortization of leasehold improvements is computed using the shorter of the lease term or estimated useful life of the asset. Additions and improvements are capitalized, while repairs and maintenance are expensed as incurred. Useful lives of each asset class are as follows:

 

Asset Category  Useful Life
Computer equipment  3-5 years
Computer software  3 years
Equipment  3-5 years
Furniture and fixtures  5-7 years
Vehicles  5 years
Leasehold improvements  Lesser of lease term or useful life
SCHEDULE OF INTANGIBLE ASSETS

 

   March 31,   December 31, 
   2025   2024 
Cost          
Goodwill  $1,404,486   $1,404,486 
Trade names and trademarks   150,000    150,000 
Customer relationships   700,000    700,000 
Cost   2,254,486    2,254,486 
Accumulated amortization          
Trade names and trademarks   (12,777)   (10,694)
Customer relationships   (76,667)   (64,167)
Accumulated amortization   (89,444)   (74,861)
Intangible assets, net  $2,165,042   $2,179,625 
SCHEDULE OF SEGMENT INFORMATION

 

   2025   2024 
   As of March 31, 
   2025   2024 
Net revenues:          
Diagnostic R&D  $—   $2,885 
Laboratory services   1,853,597    2,403,506 
Total net revenues   1,853,597    2,406,391 
           
Operating expenses:          
Diagnostic R&D   (505,739)   (442,599)
Laboratory services   (2,267,656)   (2,736,999)
General corporate activities   (1,707,341)   (1,172,023)
Total operating loss   (2,627,139)   (1,945,230)
           
Non-operating income (expense), net   (24,583)   (12,913)
Net loss before income taxes   (2,651,722)   (1,958,143)
Income tax expense   (8,695)   (3,672)
Net loss  $(2,660,417)  $(1,961,815)